Galectin-3 predicts left ventricular remodelling after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention
| Autor: | Laura Bassi, Giuseppe Di Tano, Sophie Testa, S. Pirelli, Giorgio Caretta, Renata De Maria, Marina Parolini |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class medicine.medical_treatment Galectin 3 Kaplan-Meier Estimate 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Percutaneous Coronary Intervention Internal medicine Natriuretic Peptide Brain medicine Natriuretic peptide Humans 030212 general & internal medicine Artery occlusion Myocardial infarction Prospective Studies Prospective cohort study Anterior Wall Myocardial Infarction Aged Ejection fraction Ventricular Remodeling business.industry Percutaneous coronary intervention Stroke Volume Middle Aged medicine.disease Prognosis Peptide Fragments Hospitalization ROC Curve Heart failure Cardiology Female Cardiology and Cardiovascular Medicine business Biomarkers Follow-Up Studies |
| Zdroj: | Heart (British Cardiac Society). 103(1) |
| ISSN: | 1468-201X |
| Popis: | Despite modern reperfusion therapies, left ventricular remodelling (LVR) occurs frequently after an ST-elevated myocardial infarction (STEMI) and represents a strong predictor of mortality and heart failure. Galectin-3 (Gal-3), a novel biomarker involved in inflammation, tissue repair and fibrogenesis, might be a valuable predictor of LVR.We enrolled consecutively admitted patients with a first anterior STEMI and left anterior descending artery occlusion treated by primary percutaneous coronary intervention (pPCI). Gal-3, N-terminal pro-B-type natriuretic peptide (NT-proBNP), echocardiography and cardiovascular events were evaluated 48 hours after admission, at 1 and 6 months. LVR was defined as a ≥15% increase in LV end-systolic volume.We recruited 103 patients (28% women, aged 64.6±12 years, LV ejection fraction 47±11%). Median baseline Gal-3 and NT-proBNP levels were 13.2 ng/mL (10.8-17.1 ng/mL) and 2132 pg/mL (1019-4860 pg/mL) respectively. During 6 months of follow-up, 4 patients dropped out, 7 died and 26 (28.3%) of the 92 survivors developed LVR (LVR+). LVR+ patients had higher Gal-3 levels at baseline, 1 and 6 months than LVR- (p0.0001). By univariable logistic regression, age, female gender, higher baseline Gal-3 and NT-proBNP, smaller LV end-diastolic volume (LVEDV) were associated to an increased risk of LVR. By multivariable analysis, only LVEDV (OR 0.96, 95% CI 0.93 to 0.99/1 mL change) and Gal-3 levels (OR 1.22, 95% CI 1.06 to 1.42/1 ng/mL change) independently predicted LVR (C-statistics 0.84, 95% CI 0.75 to 0.93).Gal-3 serum levels measured during hospitalisation could be clinically useful in predicting LVR among patients admitted with anterior STEMI treated by pPCI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|